Radimmune Therapeutics Selected Goodwin Biotechnology for Process Development through cGMP Manufacturing of their IgG Monoclonal Antibody and Conjugate

Thursday, November 15, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Goodwin Biotechnology:

Kayla Harris

Business Development Associate

954-327-9688

KHarris@GoodwinBio.com      or

Info@GoodwinBio.com

Radimmune Therapeutics

Robert Wittig

Chief Operating Officer

917-699-0175

RWittig@Radimmune.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store